Molecular Profile Detail

Profile Name MET positive
Gene Variant Detail

MET positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET positive ovarian cancer predicted - sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531). 24362531
MET positive non-small cell lung carcinoma conflicting Onartuzumab + Erlotinib Phase III Actionable In a Phase II clinical trial, Onartuzumab (RO5490258), in combination with Tarceva (erlotinib) demonstrated efficacy in patients with Met-positive NSCLC (PMID: 24101053). However, a subsequent Phase III clinical trial has been unable to confirm this efficacy (J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)). 24101053 detail...
MET positive non-small cell lung carcinoma sensitive Emibetuzumab + Erlotinib Phase I Actionable In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065). 27803065
MET positive non-small cell lung carcinoma sensitive Emibetuzumab + Erlotinib Phase I Actionable In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 15% (2/13) of Met-positive patients with non-small cell lung carcinoma (J Clin Oncol 31, 2013 (suppl; abstr 8093)). detail...
MET positive non-small cell lung carcinoma sensitive Telisotuzumab vedotin Phase I Actionable In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)). detail...
MET positive glioblastoma multiforme sensitive Altiratinib + Bevacizumab Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451). 26965451
MET positive glioblastoma multiforme predicted - sensitive Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451). 26965451
MET positive clear cell sarcoma predicted - sensitive Crizotinib Phase II Actionable In a Phase II trial (CREATE), Xalkori (crizotinib) treatment in MET-positive clear cell sarcoma patients resulted in an objective response rate of 3.8% (1/26) and a median progression-free survival of 131 days, similar to results achieved with first-line Adriamycin (doxorubicin) in non-selected metastatic soft tissue sarcomas (PMID: 28950372; NCT01524926). 28950372
MET positive Advanced Solid Tumor sensitive INCB028060 Phase I Actionable In a Phase I trial, INCB028060 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, as indicated by decreased whole blood Met phosphorylation level (J Clin Oncol 29: 2011 (suppl; abstr 3091)). detail...
MET positive glioblastoma multiforme sensitive Ningetinib Preclinical - Cell line xenograft Actionable In a preclinical study, Ningetinib inhibited Met phosphorylation in tumor tissue, resulted in prolonged median survival time and significantly increased life-span in cell line xenograft models of glioblastoma (Cancer Res 2014;74(19 Suppl):Abstract nr 1755). detail...
MET positive multiple myeloma predicted - sensitive Ficlatuzumab Phase I Actionable In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237). 24901237
MET positive Advanced Solid Tumor sensitive ARGX-111 Phase I Actionable In a Phase I trial, ARGX-111 demonstrated safety and resulted in some efficacy in patients with advanced solid tumors expressing MET, including a decrease in circulating tumor cells positive for MET (Journal of Clinical Oncology 33, no. 15_suppl, May 2015, 2580-2580). detail...
MET positive Advanced Solid Tumor predicted - sensitive Merestinib Preclinical - Pdx Actionable In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition correlating with Met expression level in a panel of patient-derived xenograft models of solid tumors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611). detail...
MET positive Advanced Solid Tumor no benefit AMG208 Phase I Actionable In a Phase I trial, Met expression and mutation status were not associated with response to AMG208 treatment in patients with advanced solid tumor (PMID: 26155941; NCT00813384). 26155941
MET positive triple-receptor negative breast cancer sensitive Cabozantinib Preclinical - Cell line xenograft Actionable In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786). 26432786
MET positive Advanced Solid Tumor sensitive Emibetuzumab Phase I Actionable In a Phase I trial, Emibetuzumab (LY2875358) treatment resulted in durable partial response in 4% (1/23) of Met-positive patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 8093)). detail...
MET positive myeloid neoplasm predicted - sensitive Amuvatinib Preclinical - Cell culture Actionable In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130). 24326130
MET positive non-small cell lung carcinoma sensitive Capmatinib Phase I Actionable In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)). detail...
MET positive cholangiocarcinoma predicted - sensitive Cabozantinib Phase II Emerging In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597). 28192597
Clinical Trial Phase Therapies Title Recruitment Status
NCT01662869 Phase III Onartuzumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric) Completed
NCT02205398 Phase Ib/II INC280 + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated
NCT01456325 Phase III Erlotinib Onartuzumab A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Completed
NCT01887886 Phase III Onartuzumab + Erlotinib A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation Completed
NCT01900652 Phase II Emibetuzumab + Erlotinib Emibetuzumab A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants Completed
NCT03574753 Phase II Telisotuzumab vedotin Lung-MAP S1400K: c-MET Positive Recruiting
NCT00697632 Phase I Glesatinib Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Completed
NCT03539536 Phase II Telisotuzumab vedotin Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer Recruiting
NCT01324479 Phase I Capmatinib Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors Completed
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed
NCT02323126 Phase II Nazartinib + Nivolumab INC280 + Nivolumab Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer Recruiting
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Recruiting
NCT01911507 Phase I INCB028060 + Erlotinib INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer Recruiting